{"_buckets": {"deposit": "27e1eb15-8103-4fbc-ba7b-a6cb25c01301"}, "_deposit": {"id": "3824", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "3824"}, "status": "published"}, "_oai": {"id": "oai:soar-ir.repo.nii.ac.jp:00003824", "sets": ["461:462"]}, "author_link": ["7291", "7292", "7293", "7294", "7295", "7296", "7297", "7298", "7299"], "item_1628147817048": {"attribute_name": "\u51fa\u7248\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_6_biblio_info_6": {"attribute_name": "\u66f8\u8a8c\u60c5\u5831", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2011", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "7", "bibliographicPageEnd": "1080", "bibliographicPageStart": "1073", "bibliographicVolumeNumber": "16", "bibliographic_titles": [{"bibliographic_title": "ANTIVIRAL THERAPY"}]}]}, "item_6_description_20": {"attribute_name": "\u6284\u9332", "attribute_value_mlt": [{"subitem_description": "Background: Both IL28B gene polymorphisms and serum levels of interleukin (IL)-10, IL-12p40 and IL-18 have been reported to affect the outcome of natural and pegylated interferon and ribavirin-treated HCV infection. Methods: To clarify their association and predictive value in treatment outcome of genotype 1 HCV-infected patients, we measured pretreatment serum IL-10, IL-12p40 and IL-18 levels using multiplex assays and determined IL28B gene polymorphisms (rs 8099917) in 52 cases with chronic hepatitis C. Results: High baseline levels of IL-10 (P\u003c0.001) and low levels of IL-12p40 (P\u003c0.001) were significantly associated with a non-virological response (NVR) in our cohort. The IL28B polymorphism was tested and TT, TG or GG genotypes were found in 60%, 38% and 2% of patients, respectively, with corresponding NVR rates of 10%, 60% and 100% (P\u003c0.001). Serum cytokine levels were significantly correlated with IL28B gene polymorphisms. When serum IL-10 levels were stratified at 5.0 pg/ml, NVR rates were 50% versus 0% (P=0.004) for the IT genotype and 87% versus 0% (P=0.001) for the TG or GG genotypes. Similarly, low IL-12p40 levels were associated with an NVR in patients with TG or GG genotypes (P=0.006). In multivariate analysis, high IL-10, low IL-12p40 and IL28B TG or GG genotypes were independently associated with an NVR. Conclusions: Serum IL-10 and IL-12p40 levels in combination with IL28B genotype, especially G-allele carriage, are strong predictive markers of an NVR to HCV treatment with pegylated interferon and ribavirin.", "subitem_description_type": "Abstract"}]}, "item_6_description_30": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7\uff08\u30b3\u30f3\u30c6\u30f3\u30c4\u306e\u7a2e\u985e\uff09", "attribute_value_mlt": [{"subitem_description": "Article", "subitem_description_type": "Other"}]}, "item_6_description_5": {"attribute_name": "\u5f15\u7528", "attribute_value_mlt": [{"subitem_description": "ANTIVIRAL THERAPY. 16(7):1073-1080 (2011)", "subitem_description_type": "Other"}]}, "item_6_link_3": {"attribute_name": "\u4fe1\u5dde\u5927\u5b66\u7814\u7a76\u8005\u7dcf\u89a7\u3078\u306e\u30ea\u30f3\u30af", "attribute_value_mlt": [{"subitem_link_text": "Umemura, Takeji", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.ymSpgpkh.html"}, {"subitem_link_text": "Joshita, Satoru", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.PeLNbVym.html"}, {"subitem_link_text": "Ota, Masao", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.ZefVOFkh.html"}, {"subitem_link_text": "Tanaka, Eiji", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.HFDCHekh.html"}]}, "item_6_link_67": {"attribute_name": "WoS", "attribute_value_mlt": [{"subitem_link_text": "Web of Science", "subitem_link_url": "http://gateway.isiknowledge.com/gateway/Gateway.cgi?\u0026GWVersion=2\u0026SrcAuth=ShinshuUniv\u0026SrcApp=ShinshuUniv\u0026DestLinkType=FullRecord\u0026DestApp=WOS\u0026KeyUT=000296941900016"}]}, "item_6_publisher_4": {"attribute_name": "\u51fa\u7248\u8005", "attribute_value_mlt": [{"subitem_publisher": "INT MEDICAL PRESS LTD"}]}, "item_6_relation_47": {"attribute_name": "PubMed", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "22024523"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://pubmed.ncbi.nlm.nih.gov/22024523", "subitem_relation_type_select": "PMID"}}]}, "item_6_relation_48": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "10.3851/IMP1869"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.3851/IMP1869", "subitem_relation_type_select": "DOI"}}]}, "item_6_rights_62": {"attribute_name": "\u6a29\u5229", "attribute_value_mlt": [{"subitem_rights": "This is the author\ufffdfs version of a work accepted for publication by International Medical Press. Changes resulting from the publishing process, including peer review, editing and formatting, might not be reflected in this document. A definitive version was published in Antiviral Therapy, Vol. 16, 29 July 2011, Copyright\u00a9 2011 International Medical Press"}]}, "item_6_select_64": {"attribute_name": "\u8457\u8005\u7248\u30d5\u30e9\u30b0", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_6_source_id_35": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1359-6535", "subitem_source_identifier_type": "PISSN"}]}, "item_6_source_id_39": {"attribute_name": "NII ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1359-6535", "subitem_source_identifier_type": "PISSN"}]}, "item_6_source_id_40": {"attribute_name": "\u66f8\u8a8c\u30ec\u30b3\u30fc\u30c9ID", "attribute_value_mlt": [{"subitem_source_identifier": "AA11642446", "subitem_source_identifier_type": "NCID"}]}, "item_6_text_70": {"attribute_name": "wosonly keywords", "attribute_value_mlt": [{"subitem_text_value": "NON-B-HEPATITIS; INTERFERON-ALPHA; VIRUS-INFECTION; NON-A; HEPATOCELLULAR-CARCINOMA; PEGYLATED INTERFERON; CYTOKINE PRODUCTION; RIBAVIRIN THERAPY; VIRAL CLEARANCE; PLUS RIBAVIRIN"}]}, "item_6_textarea_68": {"attribute_name": "wosonly abstract", "attribute_value_mlt": [{"subitem_textarea_value": "Background: Both IL28B gene polymorphisms and serum levels of interleukin (IL)-10, IL-12p40 and IL-18 have been reported to affect the outcome of natural and pegylated interferon and ribavirin-treated HCV infection. Methods: To clarify their association and predictive value in treatment outcome of genotype 1 HCV-infected patients, we measured pretreatment serum IL-10, IL-12p40 and IL-18 levels using multiplex assays and determined IL28B gene polymorphisms (rs 8099917) in 52 cases with chronic hepatitis C. Results: High baseline levels of IL-10 (P\u003c0.001) and low levels of IL-12p40 (P\u003c0.001) were significantly associated with a non-virological response (NVR) in our cohort. The IL28B polymorphism was tested and TT, TG or GG genotypes were found in 60%, 38% and 2% of patients, respectively, with corresponding NVR rates of 10%, 60% and 100% (P\u003c0.001). Serum cytokine levels were significantly correlated with IL28B gene polymorphisms. When serum IL-10 levels were stratified at 5.0 pg/ml, NVR rates were 50% versus 0% (P=0.004) for the IT genotype and 87% versus 0% (P=0.001) for the TG or GG genotypes. Similarly, low IL-12p40 levels were associated with an NVR in patients with TG or GG genotypes (P=0.006). In multivariate analysis, high IL-10, low IL-12p40 and IL28B TG or GG genotypes were independently associated with an NVR. Conclusions: Serum IL-10 and IL-12p40 levels in combination with IL28B genotype, especially G-allele carriage, are strong predictive markers of an NVR to HCV treatment with pegylated interferon and ribavirin."}]}, "item_creator": {"attribute_name": "\u8457\u8005", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Umemura,  Takeji", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "7291", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Joshita,  Satoru", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "7292", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoneda,  Suguru", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "7293", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Katsuyama,  Yoshihiko", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "7294", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ichijo,  Tetsuya", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "7295", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsumoto,  Akihiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "7296", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshizawa,  Kaname", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "7297", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ota,  Masao", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "7298", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tanaka,  Eiji", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "7299", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "\u30d5\u30a1\u30a4\u30eb\u60c5\u5831", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2015-09-24"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "Serum_IL-10_IL-12p40_levels_IL28B_Gene_Polymorphisms.pdf", "filesize": [{"value": "639.7 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 639700.0, "url": {"label": "Serum_IL-10_IL-12p40_levels_IL28B_Gene_Polymorphisms.pdf", "url": "https://soar-ir.repo.nii.ac.jp/record/3824/files/Serum_IL-10_IL-12p40_levels_IL28B_Gene_Polymorphisms.pdf"}, "version_id": "944e6a2a-0537-486a-8865-06c4ebf08a7d"}]}, "item_language": {"attribute_name": "\u8a00\u8a9e", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Serum interleukin (IL)-10 and IL-12 levels and IL28B gene polymorphisms: pretreatment prediction of treatment failure in chronic hepatitis C", "item_titles": {"attribute_name": "\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_title": "Serum interleukin (IL)-10 and IL-12 levels and IL28B gene polymorphisms: pretreatment prediction of treatment failure in chronic hepatitis C", "subitem_title_language": "en"}]}, "item_type_id": "6", "owner": "1", "path": ["461/462"], "permalink_uri": "http://hdl.handle.net/10091/16246", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2013-02-13"}, "publish_date": "2013-02-13", "publish_status": "0", "recid": "3824", "relation": {}, "relation_version_is_last": true, "title": ["Serum interleukin (IL)-10 and IL-12 levels and IL28B gene polymorphisms: pretreatment prediction of treatment failure in chronic hepatitis C"], "weko_shared_id": -1}